JPH11318494A - Lipase substrate solution for measuring enzymatic activity and reagent kit for measuring lipase activity - Google Patents
Lipase substrate solution for measuring enzymatic activity and reagent kit for measuring lipase activityInfo
- Publication number
- JPH11318494A JPH11318494A JP10142065A JP14206598A JPH11318494A JP H11318494 A JPH11318494 A JP H11318494A JP 10142065 A JP10142065 A JP 10142065A JP 14206598 A JP14206598 A JP 14206598A JP H11318494 A JPH11318494 A JP H11318494A
- Authority
- JP
- Japan
- Prior art keywords
- lipase
- reagent
- group
- glycero
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004882 Lipase Human genes 0.000 title claims abstract description 97
- 108090001060 Lipase Proteins 0.000 title claims abstract description 97
- 239000004367 Lipase Substances 0.000 title claims abstract description 97
- 235000019421 lipase Nutrition 0.000 title claims abstract description 97
- 239000000758 substrate Substances 0.000 title claims abstract description 72
- 235000019626 lipase activity Nutrition 0.000 title claims abstract description 54
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 128
- 230000002255 enzymatic effect Effects 0.000 title 1
- -1 aromatic hydroxy compound Chemical class 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 12
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 125000004450 alkenylene group Chemical group 0.000 claims abstract description 6
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 6
- 125000002252 acyl group Chemical group 0.000 claims abstract description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 3
- 125000003118 aryl group Chemical group 0.000 claims abstract description 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 59
- 239000012190 activator Substances 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 239000000872 buffer Substances 0.000 claims description 16
- 102000005311 colipase Human genes 0.000 claims description 13
- 108020002632 colipase Proteins 0.000 claims description 13
- 239000003945 anionic surfactant Substances 0.000 claims description 10
- 238000003028 enzyme activity measurement method Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical group C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 7
- 229960003964 deoxycholic acid Drugs 0.000 claims description 7
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 7
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 235000002906 tartaric acid Nutrition 0.000 claims description 5
- 239000011975 tartaric acid Substances 0.000 claims description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 238000005259 measurement Methods 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- 238000011088 calibration curve Methods 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000003960 organic solvent Substances 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- DNXKVOCRSQBZHO-UHFFFAOYSA-M lithium;dodecane-1-sulfonate Chemical compound [Li+].CCCCCCCCCCCCS([O-])(=O)=O DNXKVOCRSQBZHO-UHFFFAOYSA-M 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 3
- 239000001639 calcium acetate Substances 0.000 description 3
- 229960005147 calcium acetate Drugs 0.000 description 3
- 235000011092 calcium acetate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000016222 Pancreatic disease Diseases 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- RFCQDOVPMUSZMN-UHFFFAOYSA-N 2-Naphthalenethiol Chemical compound C1=CC=CC2=CC(S)=CC=C21 RFCQDOVPMUSZMN-UHFFFAOYSA-N 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical group C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION
【0001】[0001]
【発明の属する技術分野】本発明は、新規なリパーゼ基
質可溶化剤により特定のリパーゼ基質を可溶化した酵素
活性測定用リパーゼ基質溶液およびこの酵素活性測定用
リパーゼ基質溶液を使用したリパーゼ活性測定用試薬キ
ットに関する。さらに詳しくは、本発明は、リパーゼ基
質可溶化剤として1,2−ジフタノイル−sn−グリセロ
−3−ホスホコリンを使用して特定のリパーゼ基質を可
溶化した酵素活性測定用リパーゼ基質溶液およびこの酵
素活性測定用リパーゼ基質溶液を使用したリパーゼ活性
測定用試薬キットに関する。TECHNICAL FIELD The present invention relates to a lipase substrate solution for measuring an enzyme activity in which a specific lipase substrate is solubilized by a novel lipase substrate solubilizing agent, and a lipase activity measurement using the lipase substrate solution for measuring the enzyme activity. It relates to a reagent kit. More specifically, the present invention relates to a lipase substrate solution for measuring enzyme activity, in which a specific lipase substrate is solubilized using 1,2-diphthanoyl-sn-glycero-3-phosphocholine as a lipase substrate solubilizing agent. The present invention relates to a reagent kit for measuring lipase activity using a lipase substrate solution for measurement.
【0002】[0002]
【発明が解決しようとする課題】リパーゼはグリセロー
ルと脂肪酸とのグリセロールエステルを加水分解する酵
素であり、広く生物界に分布している。哺乳動物では、
食物として摂取された脂肪を消化するために、特にその
多量が膵臓に存在している。それ故、ヒトにおいては膵
疾患時に膵細胞の崩壊により、このリパーゼが膵臓から
血液中に放出されて、血液中のリパーゼ活性は健常時に
比較して高くなる。従って、血漿および血清などのそれ
ぞれの被検体中のリパーゼ活性を正確に測定することに
より膵疾患に罹っているかどうかを的確に診断すること
ができる。Lipase is an enzyme that hydrolyzes glycerol esters of glycerol and fatty acids, and is widely distributed in the living world. In mammals,
In particular, large quantities are present in the pancreas to digest fats consumed as food. Therefore, in humans, this lipase is released into the blood from the pancreas due to the destruction of pancreatic cells at the time of pancreatic disease, and the lipase activity in the blood becomes higher than in normal. Therefore, by accurately measuring the lipase activity in each subject such as plasma and serum, it is possible to accurately diagnose whether or not a patient has pancreatic disease.
【0003】たとえば、血液および血清などのそれぞれ
の被検体中のリパーゼ活性を測定するためには、他の酵
素活性測定の場合と同様に、リパーゼ活性が測定される
べき一定量の被検体と所定量のリパーゼ基質とを混合し
て酵素反応を起こさせ、この酵素反応に基づくリパーゼ
基質の変化量および/または残存量が、比色法およびU
V法(紫外線吸収法)などの分析手段によって測定され
る。しかして、これらの測定法においては、リパーゼ基
質を実質的に透明なリパーゼ基質溶液となるように可溶
化しなければならない。For example, in order to measure lipase activity in each specimen such as blood and serum, a fixed amount of the specimen whose lipase activity is to be measured is determined in the same manner as in other enzyme activity measurements. A fixed amount of lipase substrate is mixed to cause an enzymatic reaction, and the amount of change and / or residual amount of the lipase substrate based on the enzymatic reaction is determined by a colorimetric method and U
It is measured by an analysis means such as the V method (ultraviolet absorption method). Thus, in these assays, the lipase substrate must be solubilized to form a substantially clear lipase substrate solution.
【0004】しかしながら、従来のリパーゼ基質可溶化
剤によって可溶化されたリパーゼ基質を含有せしめたリ
パーゼ基質溶液は、実用上、満足できるような高い透明
度が得られず、また、仮に、高い透明度のリパーゼ基質
溶液が得られたとしても、その安定性が小さく、しばし
ば白濁や沈殿が生じるため、それが調製された後、短時
間のうちに測定に使用しなければならなかった。従っ
て、従来はこのような理由からリパーゼ活性の測定の都
度、リパーゼ基質溶液を調製しなければならなかったの
で、極めて煩雑であった。However, a lipase substrate solution containing a lipase substrate solubilized by a conventional lipase substrate solubilizing agent does not provide practically satisfactory high transparency, and suppose that the lipase substrate has high transparency. Even if a substrate solution was obtained, its stability was low and often clouded or precipitated, so that it had to be used for measurement within a short time after it was prepared. Therefore, conventionally, for each of these reasons, a lipase substrate solution had to be prepared every time the lipase activity was measured, which was extremely complicated.
【0005】本発明者らは、リパーゼ活性の測定時に被
検体であるリパーゼ含有液に含有せしめてもリパーゼの
活性を実質的に低下せしめることがないのは勿論のこ
と、リパーゼ基質を可溶化し高い透明度のリパーゼ基質
溶液が得られ、かつ、このリパーゼ基質溶液は安定性が
高く、その高い透明度を長期間にわたって維持すること
ができるようなリパーゼ基質の可溶化剤を探索すべく鋭
意研鑚を重ねた結果、1,2−ジフタノイル−sn−グリ
セロ−3−ホスホコリンがこの目的を達成し、かつ、上
記の従来技術の欠点を完全に克服し得るとの新知見を
得、この新知見に基づいて本発明に到達することができ
た。The inventors of the present invention have found that, when the lipase activity is measured, even if the lipase activity is contained in the lipase-containing solution, the lipase substrate is not substantially solubilized. A lipase substrate solution with high transparency is obtained, and this lipase substrate solution is highly stable, and intensive studies are conducted to find a lipase substrate solubilizing agent that can maintain the high transparency over a long period of time. As a result of the superposition, a new finding was obtained that 1,2-diphthanoyl-sn-glycero-3-phosphocholine achieves this object and can completely overcome the above-mentioned disadvantages of the prior art. And reached the present invention.
【0006】[0006]
【課題を解決するための手段】本第一発明は、下記の一
般式で表わされるリパーゼ基質と1,2−ジフタノイル
−sn−グリセロ−3−ホスホコリンとを少なくとも含有
することを特徴とする酵素活性測定用リパーゼ基質溶液
である。According to the first aspect of the present invention, there is provided an enzyme activity comprising at least a lipase substrate represented by the following general formula and 1,2-diphthanoyl-sn-glycero-3-phosphocholine. It is a lipase substrate solution for measurement.
【0007】[0007]
【化2】 Embedded image
【0008】[式中、Aはメチレン基もしくは炭素原子
数2〜16のアルキレン基または炭素原子数2〜16の
アルケニレン基を表わし;R1とR2とは互いに同一また
は異なって、それぞれ炭素原子数1〜20のアルキル基
もしくはアシル基、炭素原子数2〜20のアルケニル
基、炭素原子数1〜8のアルキル基で置換されていても
よいアリール基または炭素原子数が1〜8のアルキル基
から誘導されたアルアルキル基を表わす。ただし、R1
とR2とのいずれか一方が水素原子であってもよい;X
は芳香族ヒドロキシ化合物から誘導された基または芳香
族チオール化合物から誘導された基を表わす;YとZは
互いに独立に硫黄原子もしくは酸素原子を表わす;ま
た、Zはメチレン基であってもよい。]Wherein A represents a methylene group, an alkylene group having 2 to 16 carbon atoms or an alkenylene group having 2 to 16 carbon atoms; R 1 and R 2 are the same or different from each other and each has a carbon atom An alkyl group or acyl group having 1 to 20 carbon atoms, an alkenyl group having 2 to 20 carbon atoms, an aryl group optionally substituted with an alkyl group having 1 to 8 carbon atoms, or an alkyl group having 1 to 8 carbon atoms Represents an aralkyl group derived from Where R 1
One of R and R 2 may be a hydrogen atom; X
Represents a group derived from an aromatic hydroxy compound or a group derived from an aromatic thiol compound; Y and Z each independently represent a sulfur atom or an oxygen atom; and Z may be a methylene group. ]
【0009】本第二発明は、緩衝液にリパーゼ賦活剤を
溶解せしめてなる第1試薬ならびに本第一発明の酵素活
性測定用リパーゼ基質溶液である第2試薬a液およびコ
リパーゼ含有液である第2試薬b液との混合液である第
2試薬が組合わされてなるリパーゼ活性測定用試薬キッ
トである。The second invention provides a first reagent obtained by dissolving a lipase activator in a buffer, and a second reagent a solution which is a lipase substrate solution for enzyme activity measurement of the first invention and a second solution comprising a colipase-containing solution. This is a lipase activity measurement reagent kit obtained by combining a second reagent which is a mixed solution with two reagents b liquid.
【0010】[0010]
【発明の実施の形態】本第一発明の酵素活性測定用リパ
ーゼ基質溶液は上記の一般式で表わされるリパーゼ基質
(以下 特定のリパーゼ基質 と記すこともある)およ
び1,2−ジフタノイル−sn−グリセロ−3−ホスホコ
リンを有機溶媒に実質的に完全に溶解せしめた溶液であ
る。この酵素活性測定用リパーゼ基質溶液は本第二発明
のリパーゼ活性測定用試薬キットの第2試薬a液とされ
る。上記の特定のリパーゼ基質それ自体は公知であり、
たとえば、特公平6−87800号公報記載のリパーゼ
基質が好ましい。BEST MODE FOR CARRYING OUT THE INVENTION The lipase substrate solution for measuring enzyme activity according to the first aspect of the present invention comprises a lipase substrate represented by the above general formula (hereinafter sometimes referred to as a specific lipase substrate) and 1,2-diphthanoyl-sn- It is a solution in which glycero-3-phosphocholine is substantially completely dissolved in an organic solvent. This lipase substrate solution for measuring enzyme activity is used as the second reagent a solution of the reagent kit for measuring lipase activity of the second invention. The above specific lipase substrates are known per se,
For example, a lipase substrate described in JP-B-6-87800 is preferable.
【0011】すなわち、この特定のリパーゼ基質は上記
の一般式で示された化合物である。この一般式におい
て、Aであるアルキレン基は脂肪族飽和炭化水素中の異
なる炭素原子のそれぞれに結合する1個、計2個の水素
原子を除いて生ずる2価の原子団と定義され、また、ア
ルケニレン基は二重結合をもつ脂肪族炭化水素中の異な
る2個の炭素原子のそれぞれに結合する1個、計2個の
水素原子を除いて生ずる2価の原子団と定義される。A
であるアルキレン基およびアルケニレン基は、いずれも
炭素数3〜7のものが好ましい。アルキレン基として
は、たとえば、プロピレン基、α−ブチレン基、β−ブ
チレン基、γ−ブチレン基およびテトラメチレン基など
を挙げることができる。また、アルケニレン基として
は、たとえば、プロペニレン基および2−ブテニレン基
などを挙げることができる。That is, the specific lipase substrate is a compound represented by the above general formula. In this general formula, the alkylene group represented by A is defined as a divalent atomic group generated by removing two hydrogen atoms, one of which is bonded to each of the different carbon atoms in the aliphatic saturated hydrocarbon, and An alkenylene group is defined as a divalent atomic group formed by removing two hydrogen atoms, one bonded to each of two different carbon atoms in an aliphatic hydrocarbon having a double bond. A
Is preferably an alkylene group or alkenylene group having 3 to 7 carbon atoms. Examples of the alkylene group include a propylene group, an α-butylene group, a β-butylene group, a γ-butylene group, and a tetramethylene group. Examples of the alkenylene group include a propenylene group and a 2-butenylene group.
【0012】R1およびR2はそれぞれ炭素数6〜18の
ものが好ましく、炭素数8〜12のものが特に好まし
い。また、R1およびR2はそれぞれアルキル基が好まし
い。また、芳香族ヒドロキシ化合物から誘導された基ま
たは芳香族チオール化合物から誘導された基Xは、芳香
族ヒドロキシ化合物のヒドロキシル基および芳香族チオ
ール化合物のメルカプト基のそれぞれから水素原子を除
去して生じた基である。上記の芳香族ヒドロキシ化合物
および芳香族チオール化合物は、最初から発色団を形成
するか、リパーゼとの反応によって発色団に変換され得
るものであり、リパーゼ活性を阻害しないものであれば
よく、特に制限はないが、好ましい代表例として、フェ
ノール、ナフトール、チオフェノールおよびチオナフト
ールならびにこれらの誘導体であるレゾルフィン、メチ
ルレゾルフィン、フルオレセインおよびチオフルオレセ
インなどを挙げることができる。R 1 and R 2 each preferably have 6 to 18 carbon atoms, and particularly preferably have 8 to 12 carbon atoms. R 1 and R 2 are each preferably an alkyl group. Further, the group X derived from the aromatic hydroxy compound or the group X derived from the aromatic thiol compound was formed by removing a hydrogen atom from each of the hydroxyl group of the aromatic hydroxy compound and the mercapto group of the aromatic thiol compound. Group. The aromatic hydroxy compound and the aromatic thiol compound are those which form a chromophore from the beginning or can be converted into a chromophore by reaction with lipase, as long as they do not inhibit lipase activity. However, preferred representative examples include phenol, naphthol, thiophenol and thionaphthol and derivatives thereof such as resorufin, methylresorufin, fluorescein and thiofluorescein.
【0013】特定のリパーゼ基質の代表例として1,2
−o−ジラウリル−rac−グリセロ−3−グルタル酸−
(6'−メチルレゾルフィン)−エステルまたは1,2−
o−ジラウリル−rac−グリセロ−3−グルタル酸−レ
ゾルフィンエステルなどを挙げることができる。これら
のリパーゼ基質として、市販品をそのまま使用すること
ができる。市販品として、たとえば、ベーリンガー・マ
ンハイム社(Boehringer Manheim Biochemica)から販
売されている市販品がある。As representative examples of specific lipase substrates, 1,2
-O-dilauryl-rac-glycero-3-glutaric acid-
(6′-methylresorufin) -ester or 1,2-
o-Dilauryl-rac-glycero-3-glutaric acid-resorufin ester and the like can be mentioned. As these lipase substrates, commercially available products can be used as they are. Commercially available products include, for example, commercially available products from Boehringer Manheim Biochemica.
【0014】1,2−ジフタノイル−sn−グリセロ−3
−ホスホコリンは次の構造式によって示される化合物で
あり、市販品を使用することができる。市販品の代表例
としてアヴァンチ ポーラー リピッズ社(AVANTI POL
AR LIPIDS,Inc.)の商品であるL−α−レシチンジフタ
ノイルがある。1,2-diphthanoyl-sn-glycero-3
-Phosphocholine is a compound represented by the following structural formula, and a commercially available product can be used. A typical example of a commercially available product is AVANTI POL
AR LIPIDS, Inc.), which is a product of L-α-lecithin diphthanoyl.
【0015】[0015]
【化3】 Embedded image
【0016】第2試薬a液の有機溶媒は、リパーゼの活
性を阻害せず、特定のリパーゼ基質と1,2−ジフタノ
イル−sn−グリセロ−3−ホスホコリンとを溶解し、水
に対する溶解性の大きい有機溶剤であれば特に制限はな
いが、実用上、炭素数1乃至4の脂肪族低級アルコール
およびアセトンなどのそれぞれが好ましく、炭素数1乃
至4の脂肪族低級アルコールとしては、イソプロピルア
ルコールが最も好ましい。The organic solvent of the second reagent a does not inhibit the activity of lipase, dissolves a specific lipase substrate and 1,2-diphthanoyl-sn-glycero-3-phosphocholine, and has a high solubility in water. There is no particular limitation as long as it is an organic solvent, but practically preferred are aliphatic lower alcohols having 1 to 4 carbon atoms and acetone, and isopropyl alcohol is most preferred as the aliphatic lower alcohol having 1 to 4 carbon atoms. .
【0017】有機溶媒の使用量は、有機溶媒の種類およ
びリパーゼ基質の種類などによって異なり、一概に特定
し得ないが、特定のリパーゼ基質と1,2−ジフタノイ
ル−sn−グリセロ−3−ホスホコリンとの両者を溶解し
得る量の最少量とされるべきである。有機溶媒が上記の
脂肪族低級アルコールまたはアセトンである場合には、
第2試薬a液として、特定のリパーゼ基質1ミリモルに
対して、通常は、10〜250ml程度が好ましく、30
〜150ml程度が特に好ましい。The amount of the organic solvent used depends on the type of the organic solvent and the type of the lipase substrate, and cannot be specified unconditionally. However, the specific amount of the lipase substrate and 1,2-diphthanoyl-sn-glycero-3-phosphocholine Should be the minimum amount that can dissolve both. When the organic solvent is the above-mentioned aliphatic lower alcohol or acetone,
The second reagent a solution is usually preferably about 10 to 250 ml per 1 mmol of the specific lipase substrate,
Particularly preferred is about 150 ml.
【0018】また、特定のリパーゼ基質の使用量は、リ
パーゼ基質の種類、有機溶媒の種類および1,2−ジフ
タノイル−sn−グリセロ−3−ホスホコリンの量などに
よって異なり、一概に特定し得ないが、有機溶媒が上記
の脂肪族低級アルコールまたはアセトンで、特定のリパ
ーゼ基質が上記の1,2−o−ジラウリル−rac−グリ
セロ−3−グルタル酸−(6'−メチルレゾルフィン)−
エステルまたは1,2−o−ジラウリル−rac−グリセ
ロ−3−グルタル酸−レゾルフィンエステルである場合
には、第2試薬a液中の濃度として、好ましくは4〜4
0mM、特に好ましくは10〜30mMとなるような量とさ
れる。The amount of the specific lipase substrate used depends on the type of the lipase substrate, the type of the organic solvent, the amount of 1,2-diphthanoyl-sn-glycero-3-phosphocholine, and cannot be specified unconditionally. The organic solvent is the above-mentioned aliphatic lower alcohol or acetone, and the specific lipase substrate is the above-mentioned 1,2-o-dilauryl-rac-glycero-3-glutaric acid- (6′-methylresorufin)-
In the case of an ester or 1,2-o-dilauryl-rac-glycero-3-glutaric acid-resorufin ester, the concentration in the second reagent a solution is preferably 4 to 4
The amount is adjusted to be 0 mM, particularly preferably 10 to 30 mM.
【0019】一方、1,2−ジフタノイル−sn−グリセ
ロ−3−ホスホコリンの使用量は、リパーゼ基質の種類
および有機溶媒の種類などによって異なり、一概に特定
し得ないが、有機溶媒が上記の脂肪族低級アルコールま
たはアセトンである場合には、第2試薬a液中の濃度と
して、好ましくは0.3〜5mM、特に好ましくは2〜4m
Mとなるような量とされる。On the other hand, the amount of 1,2-diphthanoyl-sn-glycero-3-phosphocholine used depends on the type of lipase substrate and the type of organic solvent, and cannot be specified unconditionally. In the case of a lower alcohol or acetone, the concentration in the second reagent a solution is preferably 0.3 to 5 mM, particularly preferably 2 to 4 mM.
The amount is set to be M.
【0020】本第二発明のリパーゼ活性測定用試薬キッ
トにおいては、このような本第一発明の酵素活性測定用
リパーゼ基質溶液である第2試薬a液とコリパーゼを含
有する第2試薬b液とを混合して第2試薬としている。
すなわち、本第二発明のリパーゼ活性測定用試薬キット
は、緩衝液に、たとえば、上記のデオキシコール酸のよ
うなリパーゼ賦活剤を溶解せしめてなる第1試薬および
リパーゼ基質溶液である第2試薬a液とコリパーゼを含
有する第2試薬b液との混合液である第2試薬が組み合
わされてなるものである。第1試薬を構成する緩衝液の
調製に用いられる緩衝剤およびリパーゼ賦活剤のそれぞ
れはそれ自体公知のものでよく、それらは市販品をその
まま使用することができる。In the reagent kit for measuring lipase activity of the second invention, the second reagent a solution, which is the lipase substrate solution for enzyme activity measurement of the first invention, and the second reagent b solution containing colipase are used. Are mixed to form a second reagent.
That is, the reagent kit for measuring lipase activity of the second invention comprises a first reagent obtained by dissolving a lipase activator such as the above deoxycholic acid in a buffer solution and a second reagent a which is a lipase substrate solution. The second reagent, which is a mixture of the liquid and the second reagent b liquid containing colipase, is combined. Each of the buffer and the lipase activator used in the preparation of the buffer constituting the first reagent may be known per se, and commercially available products can be used as they are.
【0021】上記の如く、第1試薬は緩衝液に、たとえ
ば、デオキシコール酸のようなリパーゼ賦活剤を溶解せ
しめた溶液であるが、緩衝液の調製に用いられる緩衝剤
として、通常は、たとえば、グッド緩衝液の調製に使用
される両性イオン緩衝剤が好適に使用される。就中、
N,N−ビス(2−ヒドロキシエチル)−2−アミノエタ
ンスルホン酸(以下 BES と記す)またはトリス
(ヒドロキシメチル)アミノメタンが最も好ましい。As described above, the first reagent is a solution in which a lipase activator such as deoxycholic acid is dissolved in a buffer, but as a buffer used for preparing the buffer, usually, for example, The zwitterionic buffer used for the preparation of the Good buffer is preferably used. Above all,
N, N-bis (2-hydroxyethyl) -2-aminoethanesulfonic acid (hereinafter referred to as BES) or tris (hydroxymethyl) aminomethane is most preferred.
【0022】緩衝液の調製に用いられる緩衝剤の該緩衝
液中の濃度は、緩衝剤の種類によって異なるが、通常
は、5〜150mMが好ましく、15〜100mMが特に好
ましい。第1試薬のリパーゼ賦活剤としてはデオキシコ
ール酸が最も好ましいが、その他のリパーゼ賦活剤を使
用することもできる。第1試薬中のリパーゼ賦活剤の濃
度は、たとえば、リパーゼ賦活剤の種類などによって異
なり、一概に特定し得ないが、リパーゼ賦活剤がデオキ
シコール酸である場合には、通常は、10〜60mM程度
が好ましく、20〜40mM程度が特に好ましい。The concentration of the buffer in the buffer used for the preparation of the buffer varies depending on the type of the buffer, but is usually preferably from 5 to 150 mM, particularly preferably from 15 to 100 mM. Deoxycholic acid is most preferred as the lipase activator of the first reagent, but other lipase activators can also be used. The concentration of the lipase activator in the first reagent depends on, for example, the type of the lipase activator and cannot be specified unconditionally. However, when the lipase activator is deoxycholic acid, the concentration is usually 10 to 60 mM. Degree is preferable, and about 20 to 40 mM is particularly preferable.
【0023】第2試薬b液は、コリパーゼとともに、さ
らに所望によって酒石酸、水溶性のカルシウム塩などの
リパーゼ活性化剤および陰イオン界面活性剤を含有せし
めた水溶液である。上記のリパーゼ活性化剤である水溶
性のカルシウム塩としては、通常は、水溶性の有機酸ま
たは無機酸のカルシウム塩が好適に使用され、酢酸カル
シウムが最も好ましい。なお、水溶性のカルシウム塩以
外のリパーゼ活性剤を使用することを妨げない。陰イオ
ン界面活性剤として、ドデシルスルホン酸アルカリ金属
塩が好ましく、就中、ドデシルスルホン酸リチウムまた
はドデシルスルホン酸ナトリウムが最も好ましい。な
お、ドデシルスルホン酸アルカリ金属塩以外の陰イオン
界面活性剤剤を使用することを妨げない。The second reagent b solution is an aqueous solution containing, if desired, a lipase activator such as tartaric acid and a water-soluble calcium salt and an anionic surfactant together with colipase. As the water-soluble calcium salt as the lipase activator, usually, a water-soluble calcium salt of an organic acid or an inorganic acid is suitably used, and calcium acetate is most preferable. In addition, it does not prevent using a lipase activator other than a water-soluble calcium salt. As the anionic surfactant, an alkali metal salt of dodecyl sulfonic acid is preferred, and among them, lithium dodecyl sulfonate or sodium dodecyl sulfonate is most preferred. The use of an anionic surfactant other than dodecylsulfonic acid alkali metal salt is not prevented.
【0024】第2試薬b液におけるコリパーゼの濃度
は、通常行なわれているリパーゼと過剰のコリパーゼと
の共存下における1,2,3−トリブチルグリセリドを
基質としたリパーゼ活性から求められる、所謂、コリパ
ーゼの活性の大きさによって異なり一概に特定し得ない
が、たとえば、1mg当り112,000単位の活性を有
する市販コリパーゼ(ベーリンガー・マンハイム社の商
品)を使用する場合は、0.1〜50μg/ml程度が好ま
しく、1〜20μg/ml程度が特に好ましい。The concentration of colipase in the second reagent (b) is so-called colipase, which is usually determined from the lipase activity using 1,2,3-tributylglyceride as a substrate in the coexistence of lipase and excess colipase. For example, when a commercially available colipase having an activity of 112,000 units per mg (a product of Boehringer Mannheim) is used, 0.1 to 50 μg / ml is used. Degree is preferable, and about 1 to 20 μg / ml is particularly preferable.
【0025】第2試薬b液の酒石酸の濃度は、1〜10
0mM程度が好ましく、5〜50mM程度が特に好ましい。
また、第2試薬b液のリパーゼ活性化剤の濃度は、リパ
ーゼ活性化剤の種類によって異なるが、リパーゼ活性化
剤が水溶性のカルシウム塩の場合には、0.1〜10mM
程度が好ましく、0.2〜5mM程度が特に好ましい。第
2試薬b液の陰イオン界面活性剤の濃度は、陰イオン界
面活性剤の種類によって異なり、一概に特定し得ない
が、第2試薬b液として、通常は、0.1〜50mM程度
が好ましく、0.5〜10mM程度が特に好ましい。The concentration of tartaric acid in the second reagent b solution is 1 to 10
About 0 mM is preferable, and about 5 to 50 mM is particularly preferable.
The concentration of the lipase activator in the second reagent b solution varies depending on the type of the lipase activator, but when the lipase activator is a water-soluble calcium salt, the concentration is 0.1 to 10 mM.
Degree is preferable, and about 0.2 to 5 mM is particularly preferable. The concentration of the anionic surfactant in the second reagent b solution differs depending on the type of the anionic surfactant and cannot be specified unconditionally. However, the second reagent b solution usually has a concentration of about 0.1 to 50 mM. Preferably, about 0.5 to 10 mM is particularly preferable.
【0026】しかして、上記の第2試薬a液と上記の第
2試薬b液との混合比率が所定の比率とされた混合液で
ある第2試薬および上記の第1試薬が組合わされて、リ
パーゼ活性測定用試薬キットとされる。第2試薬を調製
する際の第2試薬a液と第2試薬b液との混合比率は、
リパーゼ基質の種類、有機溶媒の種類および1,2−ジ
フタノイル−sn−グリセロ−3−ホスホコリンの量なら
びに所望により含有せしめられるリパーゼ活性化剤の種
類および陰イオン界面活性剤の種類などによって異なり
一概に特定し得ないが、第2試薬a液1容量部に対して
第2試薬b液が、好ましくは、4〜18容量部、特に好
ましくは、6〜12容量部とされる。Thus, the second reagent and the first reagent, which are a mixed solution in which the mixing ratio of the second reagent a solution and the second reagent b solution is a predetermined ratio, are combined, This is a lipase activity measurement reagent kit. The mixing ratio of the second reagent a solution and the second reagent b solution when preparing the second reagent is as follows:
It depends on the type of the lipase substrate, the type of the organic solvent, the amount of 1,2-diphthanoyl-sn-glycero-3-phosphocholine, the type of the lipase activator and the type of the anionic surfactant optionally contained, and the like. Although it cannot be specified, the second reagent b liquid is used in an amount of preferably 4 to 18 parts by volume, particularly preferably 6 to 12 parts by volume per 1 part by volume of the second reagent a solution.
【0027】このリパーゼ活性測定用試薬キットを使用
した被検体中のリパーゼ活性の測定は常法の如く行われ
る。すなわち、血清などの被検体のリパーゼ活性の測定
においては、リパーゼ活性測定用試薬キットの第1試薬
の所定量に、一定量の被検体を添加して所定温度で所定
時間プレインキュベーションし、これと、予め第2試薬
a液と第2試薬b液とが所定の混合比率で混合・調製さ
れたリパーゼ活性測定用試薬キットの第2試薬の所定量
とを混合して酵素反応を起させ、その酵素活性を比色法
によって測定する。The measurement of lipase activity in a test sample using this reagent kit for measuring lipase activity is carried out in a conventional manner. That is, in the measurement of the lipase activity of an analyte such as serum, a predetermined amount of the analyte is added to a predetermined amount of the first reagent of the lipase activity measurement reagent kit, and pre-incubation is performed at a predetermined temperature for a predetermined time. A second reagent a solution and a second reagent b solution are mixed in advance at a predetermined mixing ratio with a predetermined amount of a second reagent of a reagent kit for measuring lipase activity to cause an enzyme reaction, Enzyme activity is measured by a colorimetric method.
【0028】上記の第1試薬および第2試薬のそれぞれ
は、それらの所要量を瓶などのそれぞれの容器に充填し
て1つの包装容器に収納しセットとされてリパーゼ活性
測定用試薬キットとされる。なお、本第二発明のリパー
ゼ活性測定用試薬キットの第1試薬および第2試薬はい
ずれも安定性が大きく、長期間の保存に耐えるものであ
る。Each of the first reagent and the second reagent is filled with a required amount in a container such as a bottle and stored in one packaging container to form a set, which is a reagent kit for measuring lipase activity. You. The first and second reagents of the reagent kit for measuring lipase activity of the second invention are both highly stable and can withstand long-term storage.
【0029】[0029]
【実施例】本発明を次の実施例によって、さらに具体的
に説明するが、本発明はこれらの実施例に限定されるも
のではない。 実施例1 分析方法:日立7050型自動分析装置を用いて、次の
ようにして分析を行った。なお、実施例2以降において
も同様である。EXAMPLES The present invention will be described more specifically with reference to the following examples, but the present invention is not limited to these examples. Example 1 Analysis method: Analysis was performed as follows using a Hitachi 7050 automatic analyzer. The same applies to the second and subsequent embodiments.
【0030】各第1試薬300μlに対して各被検血清
(1〜n)4μlずつを加えた混合液を、37℃で5分
間プレインキュベーションした。プレインキュベーショ
ン後、これらの混合液に第2試薬100μlずつをそれ
ぞれ添加して酵素反応を開始せしめた。A mixed solution obtained by adding 4 μl of each test serum (1 to n) to 300 μl of each first reagent was preincubated at 37 ° C. for 5 minutes. After the preincubation, 100 μl of the second reagent was added to each of these mixed solutions to start the enzyme reaction.
【0031】各被検血清(1〜n)の酵素反応開始から
約3分20秒後(26測定点)および約4分20秒後
(29測定点)のそれぞれにおける主波長600nm(副
波長700nm)の吸光度を測定し、これらをそれぞれA
1(1-n)mAbsおよびA2(1-n)mAbsとした。なお、実施例に
おける各被検血清(1〜n)として、ベーリンガー・マ
ンハイム社から市販されており、リパーゼ活性485.
6IU/lの管理用コントロール血清であるプレチパス−
U(登録商標)およびその一連の倍数希釈液を使用し
た。The main wavelength 600 nm (sub wavelength 700 nm) at about 3 minutes 20 seconds (26 measurement points) and about 4 minutes 20 seconds (29 measurement points) from the start of the enzymatic reaction of each test serum (1 to n). ) Was measured, and these were
1 (1-n) mAbs and A 2 (1-n) mAbs. Each test serum (1 to n) in the examples is commercially available from Boehringer Mannheim and has a lipase activity of 485.
Pletipas, 6 IU / l control serum for control
U® and a series of multiple dilutions thereof were used.
【0032】一方、被検血清の代りに生理食塩水を使用
した他は、上記と同様にして約3分20秒後(26測定
点)および約4分20秒後(29測定点)において測定
した吸光度をそれぞれA3mAbsおよびA4mAbsとした。こ
のように測定して得られた各被検血清(1〜n)におけ
る吸光度A1(1-n)mAbsおよびA2(1-n)mAbsならびに生理
食塩水における吸光度A3mAbsおよびA4mAbsから、次式
によって被検血清(1〜n)におけるリパーゼ活性を示
すそれぞれの吸光度A(1-n)mAbsを算出し、検量線を作
成した。 A(1-n)mAbs=[A2(1-n)mAbs−A1(1-n)mAbs]−(A4
mAbs−A3mAbs)On the other hand, measurement was performed at about 3 minutes and 20 seconds (26 measurement points) and at about 4 minutes and 20 seconds (29 measurement points) in the same manner as above, except that physiological saline was used instead of the test serum. The measured absorbances were defined as A 3 mAbs and A 4 mAbs, respectively. Absorbances A 1 (1-n) mAbs and A 2 (1-n) mAbs in each of the test sera (1 to n) obtained in this manner and absorbances A 3 and A 4 mAbs in physiological saline. Then, the respective absorbances A (1-n) mAbs showing the lipase activity in the test sera ( 1 to n) were calculated by the following formulas, and a calibration curve was prepared. A (1-n) mAbs = [A 2 (1-n) mAbs-A 1 (1-n) mAbs] - (A 4
mAbs-A 3 mAbs)
【0033】第1試薬の調製:BES(株式会社同仁化
学研究所の商品)とデオキシコール酸(ベーリンガー・
マンハイム社の商品)とをそれぞれ精製水に溶解せしめ
て、60mMBES−26.7mMデオキシコール酸混合液
である第1試薬を得た。Preparation of the first reagent: BES (a product of Dojindo Laboratories, Inc.) and deoxycholic acid (Boehringer
Was dissolved in purified water to obtain a first reagent which was a mixed solution of 60 mM BES-26.7 mM deoxycholic acid.
【0034】第2試薬の調製: (a)第2試薬a液の調製 1,2−o−ジラウリル−rac−グリセロ−3−グルタ
ル酸−(6'−メチルレゾルフィン)−エステル(ベーリ
ンガー・マンハイム社の商品)12mgをイソプロピルア
ルコール(片山化学工業株式会社の商品)1mlに溶解し
た溶液に本発明における新規なリパーゼ基質可溶化剤で
ある1,2−ジフタノイル−sn−グリセロ−3−ホスホ
コリン(アヴァンチ ポーラー リピッズ社の商品)2
1mgを溶解せしめて第2試薬a液を得た。Preparation of second reagent: (a) Preparation of second reagent a solution 1,2-o-dilauryl-rac-glycero-3-glutaric acid- (6'-methylresorufin) -ester (Boehringer Mannheim) 1,2-diphthanoyl-sn-glycero-3-phosphocholine (Avanti), a novel lipase substrate solubilizer of the present invention, was dissolved in a solution of 12 mg of isopropyl alcohol (commercial product of Katayama Chemical Industry Co., Ltd.) in 1 ml of isopropyl alcohol. Polar Lipids products) 2
1 mg was dissolved to obtain a second reagent a solution.
【0035】(b)第2試薬b液の調製 酒石酸(片山化学工業株式会社の商品)6.8mg、酢酸
カルシウム(片山化学工業株式会社の商品)0.35m
g、ドデシルスルホン酸リチウム(和光純薬株式会社の
商品)2.5mgおよびコリパーゼ(ベーリンガー・マン
ハイム社の商品)20μgを精製水4.5mlに溶解せしめ
て第2試薬b液を得た。(B) Preparation of solution b of the second reagent Tartaric acid (product of Katayama Chemical Co., Ltd.) 6.8 mg, calcium acetate (product of Katayama Chemical Co., Ltd.) 0.35 m
g, 2.5 mg of lithium dodecylsulfonate (a product of Wako Pure Chemical Industries, Ltd.) and 20 μg of colipase (a product of Boehringer Mannheim) were dissolved in 4.5 ml of purified water to obtain a second reagent b solution.
【0036】(c)第2試薬の調製 第2試薬b液4.5mlを攪拌しつつ、これに第2試薬a
液0.5mlを少量ずつ滴下して混合し、第2試薬を得
た。(C) Preparation of Second Reagent While stirring 4.5 ml of second reagent b solution, add second reagent a
0.5 ml of the liquid was added dropwise little by little and mixed to obtain a second reagent.
【0037】(d)第2試薬における各成分の濃度 上記のようにして調製された第2試薬の各成分の濃度を
以下に示す。 酒石酸 9.0mM 酢酸カルシウム 0.4mM ドデシルスルフェート・リチウム 1.8mM コリパーゼ 4 μg/ml 1,2−o−ジラウリル−rac−グリセロ−3−グルタル酸 −(6'−メチルレゾルフィン)−エステル 1.6mM イソプロピルアルコール 10 重量% 1,2−ジフタノイル−sn−グリセロ−3− ホスホコリン 2.5mM(D) Concentration of each component in the second reagent The concentration of each component of the second reagent prepared as described above is shown below. Tartaric acid 9.0 mM Calcium acetate 0.4 mM Lithium dodecyl sulfate 1.8 mM colipase 4 μg / ml 1,2-o-Dilauryl-rac-glycero-3-glutaric acid- (6′-methylresorufin) -ester 1 2.6 mM isopropyl alcohol 10% by weight 1,2-diphthanoyl-sn-glycero-3-phosphocholine 2.5 mM
【0038】結果:このようにして調製された直後の第
1試薬と第2試薬とを使用して各被検血清(1〜n)の
リパーゼ活性A(1-n)mAbsを求めた。結果を図1の直線
(イ)に示す。上記の第1試薬と第2試薬のそれぞれを
調製後、8℃で12カ月間保存し、この第1試薬と第2
試薬とを使用して各被検血清(1〜n)のリパーゼ活性
A(1-n )mAbsを求めた。結果を図1の直線(ロ)に示
す。Results: The lipase activity A (1-n) mAbs of each test serum (1-n) was determined using the first reagent and the second reagent immediately after the preparation as described above. The results are shown by the straight line (a) in FIG. After preparing each of the first and second reagents described above, store them at 8 ° C. for 12 months.
Using the reagents, the lipase activity A (1-n ) mAbs of each test serum (1-n ) was determined. The results are shown by the straight line (b) in FIG.
【0039】比較のために、リパーゼ基質可溶化剤とし
て1,2−ジフタノイル−sn−グリセロ−3−ホスホコ
リンの替りにL−α−ホスファチジルコリン(アヴァン
チポーラー リピッズ社の商品)を使用した他は、上記
と同様にして調製した直後の第1試薬と第2試薬とを使
用して各被検血清(1〜n)について同様にしてリパー
ゼ活性A(1-n)mAbsを求めた。結果を図1の直線(ハ)
に示す。また、上記の第1試薬とリパーゼ基質可溶化剤
をL−α−ホスファチジルコリンとした第2試薬のそれ
ぞれを調製後、8℃で12カ月間保存し、この第1試薬
と第2試薬とを使用して各被検血清(1〜n)のリパー
ゼ活性A(1-n)mAbsを求めた。結果を図1の直線(ニ)
に示す。For comparison, L-α-phosphatidylcholine (a product of Avanti Polar Lipds) was used in place of 1,2-diphthanoyl-sn-glycero-3-phosphocholine as a lipase substrate solubilizing agent. Lipase activity A (1-n) mAbs was determined for each of the test sera (1 to n) in the same manner using the first reagent and the second reagent immediately after preparation in the same manner as described above. The result is shown by the straight line (c) in FIG.
Shown in After preparing the first reagent and the second reagent using L-α-phosphatidylcholine as the lipase substrate solubilizing agent, respectively, store at 8 ° C. for 12 months, and use the first reagent and the second reagent. Then, the lipase activity A (1-n) mAbs of each test serum (1-n) was determined. The result is shown by the straight line in Fig. 1 (d).
Shown in
【0040】図1は各被検血清(1〜n)のそれぞれの
希釈率と上記のようにして測定されたこれらの各被検血
清(1〜n)におけるリパーゼ活性値を示す吸光度A
(1-n)mAbsとの関係線である検量線(以下 検量線 と
記す)を示している。図1に示されているように、いず
れの第1試薬および第2試薬を使用した場合でも、検量
線は直線であり、各被検血清(1〜n)のそれぞれの希
釈率とその希釈率に対応するそれぞれの被検血清(1〜
n)におけるリパーゼ活性値を示す吸光度A(1-n)mAbs
との間には直線関係が成立する。FIG. 1 shows the respective dilution rates of the test sera (1 to n) and the absorbance A indicating the lipase activity value in each of the test sera (1 to n) measured as described above.
(1-n) Indicates a calibration curve (hereinafter referred to as a calibration curve) that is a relationship curve with mAbs. As shown in FIG. 1, the calibration curve was a straight line, regardless of whether any of the first and second reagents was used, and the respective dilution rates of the test sera (1 to n) and the dilution rates thereof. Each of the test sera corresponding to
Absorbance A (1-n) mAbs indicating lipase activity value in n)
And a linear relationship is established.
【0041】また、直線(イ)および直線(ロ)のそれ
ぞれに示されているように、リパーゼ基質可溶化剤を
1,2−ジフタノイル−sn−グリセロ−3−ホスホコリ
ンとした第2試薬を使用した場合には、第1試薬および
第2試薬の調製直後および8℃での12ヵ月保存の如何
に拘わらず、それぞれの直線は原点を通過し、これらの
直線の勾配はいずれもほぼ等しかった。As shown in each of the straight line (a) and the straight line (b), a second reagent in which the lipase substrate solubilizing agent is 1,2-diphthanoyl-sn-glycero-3-phosphocholine is used. In this case, each straight line passed through the origin, regardless of whether the first and second reagents were prepared immediately or stored at 8 ° C. for 12 months, and the slopes of these straight lines were almost equal.
【0042】他方、直線(ハ)および直線(ニ)のそれ
ぞれに示されているように、リパーゼ基質可溶化剤をL
−α−ホスファチジルコリンとした第2試薬を使用した
場合には、第1試薬および第2試薬の調製直後と8℃で
の12ヵ月保存後とでは、それぞれの直線の勾配は実質
的に等しかった。しかしながら、第1試薬および第2試
薬の調製直後の場合には検量線である直線は原点を通過
したが、第1試薬および第2試薬を8℃で12ヵ月保存
した場合には、検量線である直線は調製直後のそれに比
して、直線全体が約10mAbsも大きく上方に平行移動し
ていた。これはリパーゼ基質可溶化剤を1,2−ジフタ
ノイル−sn−グリセロ−3−ホスホコリンに替えてL−
α−ホスファチジルコリンとした第2試薬は保存安定性
に欠け、長期間の保存に耐え得るものではないことを物
語っている。On the other hand, as shown by the straight line (c) and the straight line (d), the lipase substrate solubilizing agent
When the second reagent as -α-phosphatidylcholine was used, the gradients of the respective straight lines were substantially equal immediately after the preparation of the first and second reagents and after storage at 8 ° C. for 12 months. However, when the first reagent and the second reagent were prepared immediately after the preparation, the straight line as the calibration curve passed through the origin, but when the first reagent and the second reagent were stored at 8 ° C. for 12 months, the calibration curve was not obtained. One straight line had a large upward parallel displacement of about 10 mAbs compared to that immediately after preparation. This replaces the lipase substrate solubilizing agent with 1,2-diphthanoyl-sn-glycero-3-phosphocholine and L-
The second reagent, which was α-phosphatidylcholine, lacked storage stability, indicating that it was not able to withstand long-term storage.
【0043】実施例2 第1試薬における緩衝液の調製に用いられる緩衝剤をB
ESからトリス(ヒドロキシメチル)アミノメタン(片
山化学工業株式会社の商品)に替えた以外は、実施例1
と同様に行って、実施例1におけると同様な結果が得ら
れた。Example 2 The buffer used for the preparation of the buffer in the first reagent was B
Example 1 except that ES was replaced with tris (hydroxymethyl) aminomethane (a product of Katayama Chemical Co., Ltd.)
And the same results as in Example 1 were obtained.
【0044】実施例3 第2試薬a液における特定のリパーゼ基質を1,2−o
−ジラウリル−rac−グリセロ−3−グルタル酸−(6'
−メチルレゾルフィン)−エステルから1,2−o−ジ
ラウリル−rac−グリセロ−3−グルタル酸−レゾルフ
ィンエステル(ベーリンガー・マンハイム社の商品)に
替えた以外は、実施例1と同様に行って、実施例1にお
けると同様な結果が得られた。Example 3 A specific lipase substrate in the second reagent solution a was 1,2-o
-Dilauryl-rac-glycero-3-glutaric acid- (6 '
-Methylresorufin) -ester was replaced with 1,2-o-dilauryl-rac-glycero-3-glutaric acid-resorufin ester (a product of Boehringer Mannheim) except that the procedure was as in Example 1. The same result as in Example 1 was obtained.
【0045】実施例4 第1試薬における緩衝液の調製に用いられる緩衝剤をB
ESからトリス(ヒドロキシメチル)アミノメタンに替
え、さらに、第2試薬a液における特定のリパーゼ基質
を1,2−o−ジラウリル−rac−グリセロ−3−グル
タル酸−(6'−メチルレゾルフィン)−エステルから
1,2−o−ジラウリル−rac−グリセロ−3−グルタ
ル酸−レゾルフィンエステルに、また、リパーゼ基質可
溶化剤である1,2−ジフタノイル−sn−グリセロ−3
−ホスホコリンの第2試薬における濃度を2.5mMか
ら、2.0mMおよび3.8mMのいずれかに替えた以外は、
実施例1と同様に行った。Example 4 The buffer used for the preparation of the buffer in the first reagent was B
The ES was replaced with tris (hydroxymethyl) aminomethane, and the specific lipase substrate in the second reagent a solution was 1,2-o-dilauryl-rac-glycero-3-glutaric acid- (6′-methylresorufin) -Ester to 1,2-o-dilauryl-rac-glycero-3-glutaric acid-resorufin ester, and 1,2-diphthalanoyl-sn-glycero-3 which is a lipase substrate solubilizer.
-Except that the concentration of phosphocholine in the second reagent was changed from 2.5 mM to either 2.0 mM or 3.8 mM
Performed in the same manner as in Example 1.
【0046】結果を図2に示す。なお、図2において、
(ホ)乃至(チ)の各直線は次のように調製された第2
試薬を使用した場合の検量線である。すなわち、 (ホ)1,2−ジフタノイル−sn−グリセロ−3−ホス
ホコリンの濃度が2.0mMで、調製直後。 (ヘ)1,2−ジフタノイル−sn−グリセロ−3−ホス
ホコリンの濃度が2.0mMで、8℃での12ヵ月保存
後。 (ト)1,2−ジフタノイル−sn−グリセロ−3−ホス
ホコリンの濃度が3.8mMで、調製直後。 (チ)1,2−ジフタノイル−sn−グリセロ−3−ホス
ホコリンの濃度が3.8mMで、8℃での12ヵ月保存
後。FIG. 2 shows the results. In FIG. 2,
Each straight line of (e) to (h) is a second straight line prepared as follows.
It is a calibration curve when a reagent is used. (E) Immediately after preparation, the concentration of 1,2-diphthanoyl-sn-glycero-3-phosphocholine was 2.0 mM. (F) After storage at 8 ° C. for 12 months at a concentration of 1,2-diphthanoyl-sn-glycero-3-phosphocholine of 2.0 mM. (G) Immediately after preparation, the concentration of 1,2-diphthanoyl-sn-glycero-3-phosphocholine was 3.8 mM. (H) 1,2-diphthanoyl-sn-glycero-3-phosphocholine at 3.8 mM after storage at 8 ° C for 12 months.
【0047】図2に示されているように、リパーゼ基質
可溶化剤である1,2−ジフタノイル−sn−グリセロ−
3−ホスホコリンの濃度が2.0mMおよび3.8mMのそれ
ぞれであり、その各濃度の調製直後および8℃での12
ヵ月保存後の各第2試薬を使用して各被検血清(1〜
n)におけるリパーゼ活性A(1-n)mAbsを求めたとき、
1,2−ジフタノイル−sn−グリセロ−3−ホスホコリ
ンの濃度が同じ第2試薬では、長期間にわたる保存にも
拘わらず、ほぼ同一な検量線が得られた。なお、1,2
−ジフタノイル−sn−グリセロ−3−ホスホコリンの濃
度が異なるそれぞれの第2試薬を使用した場合の検量線
の勾配はそれぞれ異なり、1,2−ジフタノイル−sn−
グリセロ−3−ホスホコリン濃度2.0mMの第2試薬を
使用した場合の検量線の勾配は、1,2−ジフタノイル
−sn−グリセロ−3−ホスホコリン濃度3.8mMの第2
試薬を使用した場合のそれに比して大きかった。As shown in FIG. 2, the lipase substrate solubilizer 1,2-diphthanoyl-sn-glycero-
The concentration of 3-phosphocholine was 2.0 mM and 3.8 mM, respectively, immediately after the preparation of each concentration and 12 mM at 8 ° C.
After each month, each test serum (1 to
When the lipase activity A (1-n) mAbs in n) was determined,
With the second reagent having the same concentration of 1,2-diphthanoyl-sn-glycero-3-phosphocholine, almost the same calibration curve was obtained despite long-term storage. Note that 1, 2,
The slopes of the calibration curves when the second reagents having different concentrations of -diphthanoyl-sn-glycero-3-phosphocholine were respectively different, and 1,2-diphthanoyl-sn-
When the second reagent having a glycero-3-phosphocholine concentration of 2.0 mM was used, the gradient of the calibration curve was as follows: 1,2-diphthanoyl-sn-glycero-3-phosphocholine having a 3.8 mM second concentration.
It was larger than that when the reagent was used.
【0048】実施例5 第2試薬の陰イオン界面活性剤をドデシルスルホン酸リ
チウムからドデシルスルホン酸ナトリウム(和光純薬株
式会社の商品)に替えた以外は、実施例1と同様に行っ
て、実施例1におけると同様な結果が得られた。Example 5 The same procedure as in Example 1 was carried out except that the anionic surfactant of the second reagent was changed from lithium dodecylsulfonate to sodium dodecylsulfonate (a product of Wako Pure Chemical Industries, Ltd.). Similar results as in Example 1 were obtained.
【0049】実施例6 第2試薬の有機溶媒をイソプロピルアルコールからアセ
トン(片山化学工業株式会社の商品)に替えた以外は、
実施例1と同様に行って、実施例1におけると同様な結
果が得られた。Example 6 The organic solvent of the second reagent was changed from isopropyl alcohol to acetone (a product of Katayama Chemical Co., Ltd.).
The same operation as in Example 1 was performed, and the same result as in Example 1 was obtained.
【0050】実施例7 第2試薬の陰イオン界面活性剤をドデシルスルホン酸リ
チウムからドデシルスルホン酸ナトリウム(和光純薬株
式会社の商品)に替え、さらに、第2試薬a液における
有機溶媒をイソプロピルアルコールからアセトンに、特
定のリパーゼ基質である1,2−o−ジラウリル−rac
−グリセロ−3−グルタル酸−(6'−メチルレゾルフィ
ン)−エステルの第2試薬における濃度を1.6mMから、
0.4mMおよび3.2mMのいずれかに替えた以外は、実施
例1と同様に行った。Example 7 The anionic surfactant of the second reagent was changed from lithium dodecylsulfonate to sodium dodecylsulfonate (a product of Wako Pure Chemical Industries, Ltd.). From acetone to the specific lipase substrate 1,2-o-dilauryl-rac
The concentration of glycero-3-glutaric acid- (6′-methylresorufin) -ester in the second reagent from 1.6 mM,
The procedure was performed in the same manner as in Example 1 except that the concentration was changed to either 0.4 mM or 3.2 mM.
【0051】結果を図3に示す。なお、図3において、
(リ)乃至(オ)の各直線は次のように調製された第2
試薬を使用した場合の検量線である。すなわち、 (リ)1,2−o−ジラウリル−rac−グリセロ−3−
グルタル酸−(6'−メチルレゾルフィン)−エステルの
濃度が0.4mMで、調製直後。 (ヌ)1,2−o−ジラウリル−rac−グリセロ−3−
グルタル酸−(6'−メチルレゾルフィン)−エステルの
濃度が0.4mMで、8℃での12ヵ月保存後。 (ル)1,2−o−ジラウリル−rac−グリセロ−3−
グルタル酸−(6'−メチルレゾルフィン)−エステルの
濃度が3.2mMで、調製直後。 (オ)1,2−o−ジラウリル−rac−グリセロ−3−
グルタル酸−(6'−メチルレゾルフィン)−エステルの
濃度が3.2mMで、8℃での12ヵ月保存後。FIG. 3 shows the results. In FIG. 3,
Each of the straight lines (i) to (e) is a second straight line prepared as follows.
It is a calibration curve when a reagent is used. That is, (ii) 1,2-o-dilauryl-rac-glycero-3-
Glutaric acid- (6'-methylresorufin) -ester concentration: 0.4 mM, immediately after preparation. (Nu) 1,2-o-dilauryl-rac-glycero-3-
Glutaric acid- (6′-methylresorufin) -ester at a concentration of 0.4 mM after storage at 8 ° C. for 12 months. (R) 1,2-o-dilauryl-rac-glycero-3-
Glutaric acid- (6'-methylresorufin) -ester concentration was 3.2 mM, immediately after preparation. (E) 1,2-o-dilauryl-rac-glycero-3-
Glutaric acid- (6′-methylresorufin) -ester at a concentration of 3.2 mM after storage at 8 ° C. for 12 months.
【0052】図3に示されているように、特定のリパー
ゼ基質である1,2−o−ジラウリル−rac−グリセロ
−3−グルタル酸−(6'−メチルレゾルフィン)−エス
テルの濃度が0.4mMおよび3.2mMのそれぞれであり、
その各濃度の調製直後および8℃での12ヵ月保存後の
各第2試薬を使用して各被検血清(1〜n)におけるリ
パーゼ活性A(1-n)mAbsを求めたとき、1,2−o−ジ
ラウリル−rac−グリセロ−3−グルタル酸−(6'−メ
チルレゾルフィン)−エステルの濃度が同じ第2試薬で
は、長期間にわたる保存にも拘わらず、ほぼ同一な検量
線が得られた。なお、1,2−o−ジラウリル−rac−
グリセロ−3−グルタル酸−(6'−メチルレゾルフィ
ン)−エステルの濃度が異なるそれぞれの第2試薬にお
ける検量線の勾配はそれぞれ異なり、1,2−o−ジラ
ウリル−rac−グリセロ−3−グルタル酸−(6'−メチ
ルレゾルフィン)−エステル濃度3.2mMの第2試薬を使
用した場合の検量線の勾配は、1,2−o−ジラウリル
−rac−グリセロ−3−グルタル酸−(6'−メチルレゾ
ルフィン)−エステル濃度0.4mMの第2試薬を使用した
場合のそれに比して大きかった。As shown in FIG. 3, the concentration of the specific lipase substrate 1,2-o-dilauryl-rac-glycero-3-glutaric acid- (6'-methylresorufin) -ester was 0%. 0.4 mM and 3.2 mM, respectively.
When the lipase activity A (1-n) mAbs in each test serum (1-n) was determined using each second reagent immediately after the preparation of each concentration and after storage at 8 ° C. for 12 months, 1 With the second reagent having the same concentration of 2-o-dilauryl-rac-glycero-3-glutaric acid- (6'-methylresorufin) -ester, almost the same calibration curve was obtained despite long-term storage. Was done. In addition, 1,2-o-dilauryl-rac-
The gradients of the calibration curves for the respective second reagents having different concentrations of glycero-3-glutaric acid- (6′-methylresorufin) -ester were respectively different, and 1,2-o-dilauryl-rac-glycero-3-glutaryl was different. When the second reagent having an acid- (6′-methylresorufin) -ester concentration of 3.2 mM was used, the gradient of the calibration curve was 1,2-o-dilauryl-rac-glycero-3-glutaric acid- (6 '-Methylresorufin) -ester was larger than that when the second reagent having a concentration of 0.4 mM was used.
【0053】[0053]
【本発明の効果】本発明の酵素活性測定用リパーゼ基質
溶液は、リパーゼ基質可溶化剤として1,2−ジフタノ
イル−sn−グリセロ−3−ホスホコリンを使用すること
により、溶液の透明度が高く、以て、精度よく、リパー
ゼ活性の測定を可能とし、かつ、保存安定性が大きく、
溶液の高い透明度を長期間にわたって保持することも可
能とした。本発明の酵素活性測定用リパーゼ基質溶液の
このような優れた特性に基づいて、予め調製された該酵
素活性測定用リパーゼ基質溶液をリパーゼ活性測定用試
薬の一つとし、これと、さらに、別途予め調製されたリ
パーゼ賦活剤溶液であるリパーゼ活性測定用試薬および
コリパーゼ含有液であるリパーゼ活性測定用試薬とを組
み合わせて、リパーゼ活性測定用試薬キットとして市場
に流通せしめることができ、リパーゼ活性測定の精度の
向上は言うに及ばず、酵素活性測定用リパーゼ基質溶液
などのリパーゼ活性測定用試薬を、リパーゼ活性測定の
都度、調製しないで済むので、本発明はリパーゼ活性測
定作業の省力化にも大きく貢献し得るものである。The lipase substrate solution for enzyme activity measurement of the present invention has high transparency by using 1,2-diphthanoyl-sn-glycero-3-phosphocholine as a lipase substrate solubilizing agent. Lipase activity can be measured accurately, and the storage stability is large.
It also made it possible to maintain the high clarity of the solution over a long period of time. Based on such excellent properties of the enzyme activity measurement lipase substrate solution of the present invention, the enzyme activity measurement lipase substrate solution prepared in advance is used as one of the lipase activity measurement reagents, and further, separately. By combining a lipase activity measurement reagent that is a lipase activator solution prepared in advance and a lipase activity measurement reagent that is a colipase-containing solution, it can be distributed on the market as a lipase activity measurement reagent kit. It goes without saying that the accuracy of the lipase activity measurement reagent such as the enzyme activity measurement lipase substrate solution need not be prepared each time the lipase activity is measured. Can contribute.
【図1】本発明のリパーゼ活性測定用試薬キットを使用
して得られた各被検血清(1〜n)におけるリパーゼ活
性A(1-n)mAbsについての検量線を示す。FIG. 1 shows a calibration curve for lipase activity A (1-n) mAbs in each test serum (1-n) obtained using the lipase activity measurement reagent kit of the present invention.
【図2】本発明のリパーゼ活性測定用試薬キットを使用
して得られた各被検血清(1〜n)におけるリパーゼ活
性A(1-n)mAbsについての検量線を示す。FIG. 2 shows a calibration curve for lipase activity A (1-n) mAbs in each test serum (1-n) obtained using the lipase activity measurement reagent kit of the present invention.
【図3】本発明のリパーゼ活性測定用試薬キットを使用
して得られた各被検血清(1〜n)におけるリパーゼ活
性A(1-n)mAbsについての検量線を示す。FIG. 3 shows a calibration curve for lipase activity A (1-n) mAbs in each test serum (1-n) obtained using the lipase activity measurement reagent kit of the present invention.
Claims (7)
と1,2−ジフタノイル−sn−グリセロ−3−ホスホコ
リンとを少なくとも含有することを特徴とする酵素活性
測定用リパーゼ基質溶液。 【化1】 [式中、Aはメチレン基もしくは炭素原子数2〜16の
アルキレン基または炭素原子数2〜16のアルケニレン
基を表わし;R1とR2とは互いに同一または異なって、
それぞれ炭素原子数1〜20のアルキル基もしくはアシ
ル基、炭素原子数2〜20のアルケニル基、炭素原子数
1〜8のアルキル基で置換されていてもよいアリール基
または炭素原子数が1〜8のアルキル基から誘導された
アルアルキル基を表わす。ただし、R1とR2とのいずれ
か一方が水素原子であってもよい;Xは芳香族ヒドロキ
シ化合物から誘導された基または芳香族チオール化合物
から誘導された基を表わす;YとZは互いに独立に硫黄
原子もしくは酸素原子を表わす;また、Zはメチレン基
であってもよい。]1. A lipase substrate solution for measuring enzyme activity, comprising at least a lipase substrate represented by the following general formula and 1,2-diphthanoyl-sn-glycero-3-phosphocholine. Embedded image [Wherein A represents a methylene group or an alkylene group having 2 to 16 carbon atoms or an alkenylene group having 2 to 16 carbon atoms; R 1 and R 2 are the same or different from each other;
An alkyl group or acyl group having 1 to 20 carbon atoms, an alkenyl group having 2 to 20 carbon atoms, an aryl group optionally substituted with an alkyl group having 1 to 8 carbon atoms, or an alkyl group having 1 to 8 carbon atoms. Represents an aralkyl group derived from the above alkyl group. Provided that one of R 1 and R 2 may be a hydrogen atom; X represents a group derived from an aromatic hydroxy compound or a group derived from an aromatic thiol compound; Independently represents a sulfur atom or an oxygen atom; Z may be a methylene group. ]
−rac−グリセロ−3−グルタル酸−(6'−メチルレゾ
ルフィン)−エステルまたは1,2−o−ジラウリル−r
ac−グリセロ−3−グルタル酸−レゾルフィンエステル
である請求項1記載の酵素活性測定用リパーゼ基質溶
液。2. The method according to claim 1, wherein the lipase substrate is 1,2-o-dilauryl-rac-glycero-3-glutaric acid- (6′-methylresorufin) -ester or 1,2-o-dilauryl-r.
The lipase substrate solution for enzyme activity measurement according to claim 1, which is ac-glycero-3-glutaric acid-resorufin ester.
なる第1試薬ならびに請求項1または2記載の酵素活性
測定用リパーゼ基質溶液である第2試薬a液およびコリ
パーゼ含有液である第2試薬b液との混合液である第2
試薬が組合わされてなるリパーゼ活性測定用試薬キッ
ト。3. A first reagent obtained by dissolving a lipase activator in a buffer, a second reagent a which is a lipase substrate solution for enzyme activity measurement according to claim 1 or 2, and a second reagent which is a colipase-containing liquid. The second liquid which is a mixed liquid with the liquid b
A reagent kit for measuring lipase activity comprising a combination of reagents.
る請求項3記載のリパーゼ活性測定用試薬キット4. The reagent kit for measuring lipase activity according to claim 3, wherein the lipase activator is deoxycholic acid.
剤、陰イオン界面活性剤およびコリパーゼを含有する水
溶液である請求項3記載のリパーゼ活性測定用試薬キッ
ト。5. The reagent kit for measuring lipase activity according to claim 3, wherein the second reagent b solution is an aqueous solution containing tartaric acid, a lipase activator, an anionic surfactant and colipase.
塩である請求項5記載のリパーゼ活性測定用試薬キッ
ト。6. The reagent kit for measuring lipase activity according to claim 5, wherein the lipase activator is a water-soluble calcium salt.
酸アルカリ金属塩である請求項5または6記載のリパー
ゼ活性測定用試薬キット。7. The reagent kit for measuring lipase activity according to claim 5, wherein the anionic surfactant is an alkali metal salt of dodecylsulfonic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14206598A JP4018237B2 (en) | 1998-05-11 | 1998-05-11 | Lipase substrate solution for enzyme activity measurement and reagent kit for lipase activity measurement |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14206598A JP4018237B2 (en) | 1998-05-11 | 1998-05-11 | Lipase substrate solution for enzyme activity measurement and reagent kit for lipase activity measurement |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11318494A true JPH11318494A (en) | 1999-11-24 |
JP4018237B2 JP4018237B2 (en) | 2007-12-05 |
Family
ID=15306623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14206598A Expired - Lifetime JP4018237B2 (en) | 1998-05-11 | 1998-05-11 | Lipase substrate solution for enzyme activity measurement and reagent kit for lipase activity measurement |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4018237B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008307048A (en) * | 2007-05-16 | 2008-12-25 | Fujifilm Corp | Method for producing dry analytical element for pancreatic lipase measurement |
WO2016024549A1 (en) * | 2014-08-12 | 2016-02-18 | 株式会社シノテスト | Method for producing substrate solution for lipase activity assay, and method for simplifying production |
WO2016204276A1 (en) * | 2015-06-19 | 2016-12-22 | 株式会社シノテスト | Substrate solution for lipase activity measurement, and method and measurement reagent for measurement of lipase activity in sample |
WO2018056162A1 (en) * | 2016-09-20 | 2018-03-29 | 株式会社シノテスト | Lipase activity measuremnet method and reagent, and substrate solution for use in measurement of activity of lipase |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61254197A (en) * | 1985-05-03 | 1986-11-11 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Visual measuring method and reagent for lipase substrate andlipase |
JPH04257596A (en) * | 1991-02-12 | 1992-09-11 | Fuji Photo Film Co Ltd | Glycerol derivative |
JPH09215500A (en) * | 1996-02-13 | 1997-08-19 | Towns:Kk | Substrate solution for lipase analysis and reagent solution kid for lipase analysis |
-
1998
- 1998-05-11 JP JP14206598A patent/JP4018237B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61254197A (en) * | 1985-05-03 | 1986-11-11 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Visual measuring method and reagent for lipase substrate andlipase |
JPH04257596A (en) * | 1991-02-12 | 1992-09-11 | Fuji Photo Film Co Ltd | Glycerol derivative |
JPH09215500A (en) * | 1996-02-13 | 1997-08-19 | Towns:Kk | Substrate solution for lipase analysis and reagent solution kid for lipase analysis |
Non-Patent Citations (2)
Title |
---|
BIOCHIM.BIOPHYS.ACTA,VOL.555(1979)P.147-167, JPN4007007202, ISSN: 0000846153 * |
BIOCHIM.BIOPHYS.ACTA,VOL.555(1979)P.147-167, JPNX007047547, ISSN: 0000890075 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008307048A (en) * | 2007-05-16 | 2008-12-25 | Fujifilm Corp | Method for producing dry analytical element for pancreatic lipase measurement |
WO2016024549A1 (en) * | 2014-08-12 | 2016-02-18 | 株式会社シノテスト | Method for producing substrate solution for lipase activity assay, and method for simplifying production |
US10494659B2 (en) | 2014-08-12 | 2019-12-03 | Shino-Test Corporation | Process for producing substrate solution for measuring lipase activity, and method for simplifying production |
WO2016204276A1 (en) * | 2015-06-19 | 2016-12-22 | 株式会社シノテスト | Substrate solution for lipase activity measurement, and method and measurement reagent for measurement of lipase activity in sample |
US10633687B2 (en) | 2015-06-19 | 2020-04-28 | Shino-Test Corporation | Substrate solution for measuring lipase activity, and method and reagent for measuring lipase activity in sample |
WO2018056162A1 (en) * | 2016-09-20 | 2018-03-29 | 株式会社シノテスト | Lipase activity measuremnet method and reagent, and substrate solution for use in measurement of activity of lipase |
Also Published As
Publication number | Publication date |
---|---|
JP4018237B2 (en) | 2007-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2344055C (en) | Method for fractional determination of cholesterol in lipoproteins and a reagent therefor | |
US4543326A (en) | Stabilization of oxidase | |
CA2597792C (en) | Method, reagent and kit for determination of cholesterol in remnant-like particles (rlp) | |
CS244665B2 (en) | Method of enzymatic determination of enzyme substrates | |
US4414326A (en) | Diagnostic agents | |
US7811779B2 (en) | Method of multiquantification for cholesterol of low-density lipoprotein | |
JP4527950B2 (en) | Lipid measuring reagent | |
JP4220603B2 (en) | Method for measuring platelet activating factor acetylhydrolase activity | |
JP4018237B2 (en) | Lipase substrate solution for enzyme activity measurement and reagent kit for lipase activity measurement | |
JP3677452B2 (en) | Procedures and diagnostic products for the determination of triglycerides in lipoproteins | |
JP2005278626A (en) | Method for stabilizing enzymatic measuring reagent | |
CA2287129C (en) | Stabilization of biological fluids by addition of sterol esters | |
JP3601648B2 (en) | Biological component measuring reagent and measuring method | |
EP0044432B1 (en) | Stabilized enzymatic solutions and method for determining total cholesterol in human serum | |
JP4130724B2 (en) | Reagent containing chelating substance | |
US4279994A (en) | Lipase determination method and reagent | |
US5378609A (en) | Lipase single reagent system | |
US4007091A (en) | Method for measuring the activity of lecithin cholesterol acyl transferase and lecithin substrate solution useful therefor | |
JP2000287700A (en) | Measurement of lipase activity value, cholesterol concentration and neutral lipid concentration | |
JP2003227798A (en) | Method for stabilizing reagent composition and stabilized reagent composition | |
JP4034851B2 (en) | Specific measurement method and measurement composition for low density lipoprotein cholesterol, and specific measurement method for low density and high density lipoprotein cholesterol | |
JPH09215500A (en) | Substrate solution for lipase analysis and reagent solution kid for lipase analysis | |
JPH0151782B2 (en) | ||
JP3057183B2 (en) | Stabilization of fluorescent substrate solution | |
JP2003230400A (en) | Reagent composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070508 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070709 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070711 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070904 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070920 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100928 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100928 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110928 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110928 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120928 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120928 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130928 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |